Last reviewed · How we verify
docetaxel, cisplatin, and capecitabine
Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death. Capecitabine is a prodrug of 5-fluorouracil, which inhibits thymidylate synthase, disrupting DNA synthesis.
Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, causing cell death. Capecitabine is a prodrug of 5-fluorouracil, which inhibits thymidylate synthase, disrupting DNA synthesis. Used for Metastatic breast cancer, Metastatic non-small cell lung cancer, Adjuvant treatment of node-positive breast cancer.
At a glance
| Generic name | docetaxel, cisplatin, and capecitabine |
|---|---|
| Also known as | TPX induction chemotherapy |
| Sponsor | Sun Yat-sen University |
| Drug class | Taxane, Platinum-based chemotherapeutic, Antimetabolite |
| Target | Microtubules, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Docetaxel binds to tubulin, preventing microtubule polymerization and causing cell cycle arrest at the G2/M phase. Cisplatin forms platinum-DNA adducts, triggering apoptosis. Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase, leading to DNA damage and cell death.
Approved indications
- Metastatic breast cancer
- Metastatic non-small cell lung cancer
- Adjuvant treatment of node-positive breast cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Diarrhea
- Fatigue
- Mucositis
- Hair loss
- Neuropathy
Key clinical trials
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (PHASE3)
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension (PHASE3)
- Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC) (PHASE2)
- A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma (PHASE2)
- A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- The Management of Metastatic Neck Nodes in N2/3 Hypopharyngeal Squamous Cell Carcinoma (NA)
- Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA (PHASE3)
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- docetaxel, cisplatin, and capecitabine CI brief — competitive landscape report
- docetaxel, cisplatin, and capecitabine updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI